Market Report Focused on Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Relapsed chronic lymphocytic leukemia (CLL) is a type of cancer chronic lymphocytic leukemia, that the cancer has come back after remission was achieved with treatment. Symptoms include weakness, feeling tired, weight loss, fever, night sweats and enlarged lymph nodes, pain or a sense of fullness in the belly which is caused by an enlarged spleen.

To access full report with TOC, please visit Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 21, 20 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Relapsed Chronic Lymphocytic Leukemia (CLL).

Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG AbbVie Inc Aptevo Therapeutics Inc Astellas Pharma Inc. Astex Pharmaceuticals Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cellular Biomedicine Group, Inc. Cyclacel Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. Hutchison MediPharma Limited ImmunoGen, Inc. Immunomedics, Inc. Incyte Corporation Innate Pharma S.A. Juno Therapeutics Inc. Karyopharm Therapeutics, Inc. LFB S.A. Lymphocyte Activation Technologies, S.A. Millennium Pharmaceuticals Inc MorphoSys AG Novartis AG Oncternal Therapeutics, Inc. Ono Pharmaceutical Co., Ltd. PIQUR Therapeutics AG Rhizen Pharmaceuticals S.A. Sanofi TRACON Pharmaceuticals Inc Tragara Pharmaceuticals, Inc. Verastem, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###